BioCryst Pharma (BCRX) Tops Q2 EPS by 11c, provides product guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.00 +4.71%
EPS Growth %: -13.3%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: -13.3%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.06), $0.11 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $109.33 million versus the consensus estimate of $98.3 million.
Guidance:
Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)—
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allison Transmission to Join S&P MidCap 400; Goodyear Tire & Rubber to Join S&P SmallCap 600
- UBS Upgrades DLocal Limited (DLO) to Buy
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
